Literature DB >> 15448583

Generalized anxiety disorder: acute and chronic treatment.

Moira A Rynn1, Olga Brawman-Mintzer.   

Abstract

Clinical and epidemiological data suggest that generalized anxiety disorder (GAD) is a chronic illness causing patients to suffer for many years leading to significant distress in daily life functioning. The literature suggests the several conclusions. GAD is a disorder in need of appropriate treatment and often has a chronic course with comorbid conditions, such as major depression and other anxiety disorders. Benzodiazepines, while effective anxiolytic agents acutely, when prescribed for >4 weeks cause rebound anxiety and following prolonged therapy may lead to withdrawal symptoms. Antidepressants cause significant anxiety relief compared with placebo and for psychosocial treatment cognitive-behavioral therapy is an efficacious psychosocial treatment. Many GAD patients are in need of long-term medication management. Furthermore, there is limited data for patients diagnosed with GAD the treatment outcome with the combination of medication and psychotherapy both acutely and long-term; how to best sequence these treatments; for those patients who do not meet remission criteria what is the ideal approach for augmentation; and for patients with treatment-refractory GAD the empirical evidence is lacking on medication switching and augmentation strategies. Research is needed in the area of developing treatment strategies for patients suffering from treatment-refractory GAD. There is still an urgent need to explore treatment combinations and duration strategies in the management of patients suffering with GAD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448583     DOI: 10.1017/s1092852900022367

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  12 in total

1.  Open Trial of Modular Cognitive-Behavioral Therapy in the Treatment of Anxiety Among Late Adolescents with Autism Spectrum Disorder.

Authors:  Jillian M Wise; Sandra L Cepeda; D Luis Ordaz; Nicole M McBride; Mark A Cavitt; Flora R Howie; Leanne Scalli; Jill Ehrenreich-May; Jeffrey J Wood; Adam B Lewin; Eric A Storch
Journal:  Child Psychiatry Hum Dev       Date:  2019-02

Review 2.  Pediatric generalized anxiety disorder: epidemiology, diagnosis, and management.

Authors:  Courtney Pierce Keeton; Amie C Kolos; John T Walkup
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

3.  The role of duloxetine in the treatment of anxiety disorders.

Authors:  Domenico De Berardis; Nicola Serroni; Alessandro Carano; Marco Scali; Alessandro Valchera; Daniela Campanella; Alessandro D'Albenzio; Berardo Di Giuseppe; Francesco Saverio Moschetta; Rosa Maria Salerno; Filippo Maria Ferro
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

Review 4.  Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.

Authors:  Keming Gao; David V Sheehan; Joseph R Calabrese
Journal:  Expert Rev Neurother       Date:  2009-08       Impact factor: 4.618

5.  Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.

Authors:  Eric J Lenze; Bruce L Rollman; M Katherine Shear; Mary Amanda Dew; Bruce G Pollock; Caroline Ciliberti; Michelle Costantino; Sara Snyder; Peichang Shi; Edward Spitznagel; Carmen Andreescu; Meryl A Butters; Charles F Reynolds
Journal:  JAMA       Date:  2009-01-21       Impact factor: 56.272

6.  Psychiatric evaluation of the agitated patient: consensus statement of the american association for emergency psychiatry project Beta psychiatric evaluation workgroup.

Authors:  Keith R Stowell; Peter Florence; Herbert J Harman; Rachel L Glick
Journal:  West J Emerg Med       Date:  2012-02

Review 7.  Pharmacotherapy of anxiety disorders: a critical review.

Authors:  Nastassja Koen; Dan J Stein
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

Review 8.  Mexazolam: clinical efficacy and tolerability in the treatment of anxiety.

Authors:  Hélder Fernandes; Ricardo Moreira
Journal:  Neurol Ther       Date:  2014-03-29

9.  Cannabis and the Anxiety of Fragmentation-A Systems Approach for Finding an Anxiolytic Cannabis Chemotype.

Authors:  Brishna S Kamal; Fatima Kamal; Daniel E Lantela
Journal:  Front Neurosci       Date:  2018-10-22       Impact factor: 4.677

10.  Three-dimensional scoring of zebrafish behavior unveils biological phenomena hidden by two-dimensional analyses.

Authors:  Simone Macrì; Daniele Neri; Tommaso Ruberto; Violet Mwaffo; Sachit Butail; Maurizio Porfiri
Journal:  Sci Rep       Date:  2017-05-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.